Reablation of atrial fibrillation targeting electrogram dispersion in patients with isolated veins: The RESTART trial.

John D Hummel¹, Paul C Zei², Mark Metzl³, Isabel Deisenhofer⁴, Haroon Rashid⁵, Gustavo Morales⁶, Jérôme Horvilleur⁷, Stavros Mountantonakis⁸, Jean-Paul Albenque⁹, Smit Vasaiwala¹⁰, Tom De Potter¹¹, Adi Lador¹², Anthony Magnano¹³, Alexandru B Chicos¹⁴, Joshua Silverstein¹⁵, Daniel Guerrero¹⁶, Shirley Beguin¹⁶, Anas El-Benna¹⁶, Marie-Sophie Nguyen-Tu¹⁶, Sabine Lotteau¹⁶, Paola Milpied¹⁶, Théophile Mohr Durdez¹⁶, Jérôme Kalifa¹⁶, Clément Bars¹⁷, Julien Seitz¹⁷, Benjamin D'Souza¹⁸, Daniel H Cooper¹⁹, Devi Nair²⁰, Dhanunjaya Lakkireddy²¹

¹The Ohio State University Wexner Medical Center, Columbus, Ohio. Electronic address: john.Hummel@osumc.edu.

²Mass General Brigham, Harvard Medical School, Boston, Massachusetts.

³Endeavor Health, Glenview, Illinois.

⁴Department of Electrophysiology, Technical University of Munich (TUM), German Heart Center Munich, Munich, Germany.

⁵Inova Heart and Vascular Institute and Virginia Heart, Fairfax, Virginia.

⁶Arrhythmia Institute at Grandview Medical Center, Birmingham, Alabama.

⁷Hôpital Privé Jacques Cartier - Ramsay Santé - Institut Cardiovasculaire Paris Sud, Massy, France.

⁸Northwell Cardiovascular Institute, New Hyde Park, New York.

⁹Clinique Pasteur, Toulouse, France.

¹⁰Loyola University Medical Center, Maywood, Illinois.

¹¹Cardiovascular Center, AZORG, Aalst, Belgium.

¹²Houston Methodist DeBakey Heart and Vascular Center and Research Institute, Houston, Texas.

¹³Ascension St. Vincent's Medical Center, Jacksonville, Florida.

¹⁴Northwestern University, Evanston, Illinois.

¹⁵Allegheny Health Network, Pittsburgh, Pennsylvania.

¹⁶Volta Medical, Marseille, France.

¹⁷Volta Medical, Marseille, France; Hôpital Saint Joseph, Marseille, France.

¹⁸Penn Presbyterian Medical Center, Philadelphia, Pennsylvania.

¹⁹Washington University, St. Louis, Missouri.

²⁰St. Bernards Medical Center & Arrhythmia Research Group, Jonesboro, Arkansas.

²¹The Kansas City Heart Rhythm Institute, Overland Park, Kansas.

PubMed DOI

Abstract

BACKGROUND: Pulmonary vein (PV) isolation is a well-established treatment for atrial fibrillation (AF), however, strategies for patients with recurrent AF and isolated PVs remain elusive. OBJECTIVE: This study aimed to evaluate the effectiveness of a personalized artificial intelligence (AI)-guided spatiotemporal dispersion mapping and ablation in patients undergoing a repeat ablation and whose P…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

Volta Medical
affiliation

MeSH Terms

Humans0Atrial Fibrillation*Catheter Ablation*Pulmonary Veins*Female0Male0Prospective Studies0Treatment Outcome0Middle Aged0Recurrence0Heart Conduction System*Follow-Up Studies0Electrocardiography, Ambulatory0Reoperation0Artificial Intelligence*Surgery, Computer-Assisted*Electrophysiologic Techniques, Cardiac*

Keywords

Artificial intelligence–guided ablationAtrial fibrillationDispersionPulmonary vein isolationRedo ablationSpatiotemporal dispersion

Article Info

PMID: 41638617
DOI: 10.1016/j.hrthm.2026.01.042
Received: August 11, 2025
Accepted: January 26, 2026

How to Cite

Hummel JD et al. Reablation of atrial fibrillation targeting electrogram dispersion in patients with isolated veins: The RESTART trial. Heart Rhythm2026;23(5):1083-1090. doi:10.1016/j.hrthm.2026.01.042

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.